AURA BIOPHARM SIGNS AN AGREEMENT WITH SMERUD MEDICAL RESEARCH INTERNATIONAL AS TO DEVELOP AUR-1001
AURA Biopharm AS has entered a partnership with Smerud Medical Research International AS (SMERUD). The agreement describes an alliance which includes co-investment in, and co-development of AUR-1001 in the treatment of Antiphospholipid syndrome. SMERUD is a contract research organization with a dedicated business unit for co-development of drug candidates.
This partnership results from the exciting business model developed by AURA. By virtual operations and collaborative alliances AURA can deliver future therapies to the market in a quick and effective mode of operation.
This partnership between AURA and SMERUD is a major step towards reaching key milestones and demonstrating the value drivers of AUR-1001.